Science and research

Anti-Nucleophosmin Immune Response in Patients with Acute Myeloid Leukemia (AML)

The immune response is turning to be an important factor contributing to leukemia eradication. About one third of AML patients have specific C-terminal mutations in the gene for nucleophosmin 1 (NPM1) which are considered to be a positive prognostic factor. However, the underlying mechanisms are unknown. We have recently identified a set of HLA class I alleles which are likely to present nucleophosmin-derived peptides and thus to mediate a spontaneous anti-nucleophosmin immune response.

Our current research in this area includes further characterization of the effect of patient HLA type on the disease course, experimental evidence of the existence of nucleophosmin-specific immune cells and the screen for the reasons of immune response failure in patients with suitable HLA type (grant project No 16-30268A from the Agency for Health Research of the Czech Republic).

Quick contact

Head of Science and Research Division
Tel:+420 221 977 208

Deputy head of Science and Research Division
Tel:+420 221 977 269
Tel:+420 221 977 364

Tel:+420 221 977 247

Opening hours

Mo – Fr: 7:00–18:00
Weekends: 9:00–13:00

Mo – Fr: 7:00–10:30

Inpatient department
Mo – Fr: 13:00–18:00

ICU and Transplant unit
Mo – Fr: 14:00–17:00

How to find us


Ústav hematologie a krevní transfuze
(​Institute of Hematology and Blood Transfusion)

U Nemocnice 2094/1
128 00 Praha 2

The nearest underground station: Karlovo náměstí (line B)

The nearest tram station: Karlovo náměstí (10, 16, 22), Moráň (3, 6, 10, 16, 18, 24)

The nearest bus station: U Nemocnice (148), Karlovo náměstí (176)

How to get here